Pharmacogenetic determinants of MTX treatment efficacy. Results of all performed analyses are shown in Supplementary Table 3 (available with the online version of this article).
| SNP | Nonresponse to MTX | Time to Inactive Disease | ||||
|---|---|---|---|---|---|---|
| Univariate Analysis | Penalized Cox Regression OR, | Univariate Analysis | Penalized Cox Regression, HR | |||
| Associated Allele, OR, 95% CI | p | Associated Allele, HR, 95% CI | p | |||
| Folate pathway | ||||||
| MTHFR rs1801133 | T, 0.64, 0.27–1.49 | 0.299 | 1 | T, 1, 0.64–1.56 | 0.999 | 1 |
| MTHFR rs1801131 | C, 0.66, 0.28–1.52 | 0.325 | 1 | C, 1.26, 0.8–1.97 | 0.317 | 1.19 |
| MTR rs1805087 | G, 0.96, 0.38–2.28 | 0.921 | 1 | G, 1.64, 1.02–2.63 | 0.042 | 1.58 |
| MTRR rs1801394 | G, 1.22, 0.37–5.08 | 0.752 | 1 | G, 0.81, 0.43–1.51 | 0.509 | 1 |
| Adenosine pathway | ||||||
| ATIC rs2372536 | G, 0.99, 0.43–2.33 | 0.984 | 1 | G 1.18, 0.76–1.85 | 0.457 | 1.14 |
| ITPA rs1127354 | A, 1.57, 0.42–5.17 | 0.480 | 1 | A, 1.6, 0.82–3.11 | 0.170 | 1.36 |
| MTX transporters | ||||||
| ABCC2 rs2804402 | G, 0.37, 0.14–0.99 | 0.048 | 1 | G, 1.14, 0.65–2.01 | 0.640 | 1.07 |
| ABCC2 rs2273697 | A, 1.06, 0.45–2.44 | 0.894 | 1 | G wt, 0.62, 0.39–0.99 | 0.043 | 1.55 |
Wt was associated with tested variable, and in all other analyses, polymorphic allele was associated with tested variable. Significant data are in bold face. MTX: methotrexate; SNP: single-nucleotide polymorphism; wt: wild-type.